The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer

S. Vivekanandan, FRCR,* D.B. Landau, FRCR,† N. Counsell, MSc,‡ D.R. Warren, PhD,* A. Khwanda, MD,§ S.D. Rosen, FACC,¶ E. Parsons, BHSc,¶ Y. Ngai, BSc,† L. Farrelly, MSc,¶ L. Hughes, NDipSci,‡ M.A. Hawkins, MD,* and J.D. Fenwick, PhD##

*Department of Oncology and CRUK MRC, Oxford Institute for Radiation Oncology, Gray Laboratories, University of Oxford, Oxford, UK; †Department of Oncology, Guy’s & St. Thomas’ NHS Trust, King’s College London, UK; ‡Cancer Research UK & UCL Cancer Trials Centre Cancer Institute, University College London, London, UK; ¶Department of Cardiology, Ealing Hospital and Imperial College London, UK; ||Department of Cardiology, Ealing and Royal Brompton Hospitals & Imperial College, London, UK; ‡Department of Radiotherapy Trials Quality Assurance, Mount Vernon Hospital, Middlesex, UK; §Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK; and ##Department of Physics, Clatterbridge Cancer Centre, Wirral, UK

Received Oct 13, 2016, and in revised form Apr 7, 2017. Accepted for publication Apr 19, 2017.

Summary
We explored associations between all-cause death rate (DR), cardiac radiation doses, and electrocardiographic changes in 78 patients with locally advanced non-small cell lung cancer treated in IDEAL-CRT, a trial of isotoxically escalated concurrent chemoradiation delivering tumor doses of 63 to 73 Gy.

Purpose: The heart receives high radiation doses during radiation therapy of advanced-stage lung cancer. We have explored associations between overall survival, cardiac radiation doses, and electrocardiographic (ECG) changes in patients treated in IDEAL-CRT, a trial of isotoxically escalated concurrent chemoradiation delivering tumor doses of 63 to 73 Gy.

Methods and Materials: Dosimetric and survival data were analyzed for 78 patients. The whole heart, pericardium, AV node, and walls of left and right atria (LA/RA-Wall) and ventricles (LV/RV-Wall) were outlined on radiation therapy planning scans, and differential dose-volume histograms (dDVHs) were calculated. For each structure, dDVHs were approximated using the average dDVH and the 10 highest-ranked structure-specific principal components (PCs). ECGs at baseline and 6 months after radiation therapy were analyzed for 53 patients, dichotomizing patients according to presence or absence of electrocardiographic changes.

Supplementary material for this article can be found at www.redjournal.org.
between higher DR and conduction or ischemic/pericarditis-like changes on ECG at 6 months, and between higher DR and higher heart or left atrial wall volumes receiving 63 to 69 Gy.

absence of “any ECG change” (conduction or ischemic/pericarditis-like change). All-cause death rate (DR) was analyzed from the start of treatment using Cox regression.

**Results:** 38% of patients had ECG changes at 6 months. On univariable analysis, higher scores for LA-Wall-PC6, Heart-PC6, “any ECG change,” and larger planning target volume (PTV) were significantly associated with higher DR ($P = .003$, .009, .029, and .037, respectively). Heart-PC6 and LA-Wall-PC6 represent larger volumes of whole heart and left atrial wall receiving 63 to 69 Gy. Cardiac doses ≥63 Gy were concentrated in the LA-Wall, and consequently Heart-PC6 was highly correlated with LA-Wall-PC6. “Any ECG change,” LA-Wall-PC6 scores, and PTV size were retained in the multivariable model.

**Conclusions:** We found associations between higher DR and conduction or ischemic/pericarditis-like changes on ECG at 6 months, and between higher DR and higher Heart-PC6 or LA-Wall-PC6 scores, which are closely related to heart or left atrial wall volumes receiving 63 to 69 Gy in this small cohort of patients.

---

**Introduction**

Definitive chemoradiation (CRT) is the standard of care for locally advanced non-small cell lung cancer (NSCLC) (1). For more than 30 years the accepted radiation therapy dose was 60 to 63 Gy in 1.8- to 2.0-Gy fractions, established by Radiation Therapy Oncology Group trial RTOG-7301 (2, 3). Overall survival (OS) is poor at these dose levels, with high local failure rates stimulating interest in dose escalation. Outcomes modeling suggests a tumor dose response (4), and results from early-phase studies indicated that concurrent CRT might be safe up to 74 Gy (5-12). However, the RTOG-0617 phase 3 trial of dose escalation has reported a significantly lower OS for 74 Gy than for 60 Gy in daily 2-Gy fractions, triggering efforts to identify reasons for the reduced survival (13). An RTOG-0617 analysis found negative associations between OS and high heart volumes receiving more than 5 Gy or 40 Gy (13, 14). A recent meta-analysis of randomized trials in NSCLC found that for concurrent CRT treatments, higher radiation doses result in poorer OS, possibly partly because of higher levels of toxicity in the presence of concurrent chemotherapy (15).

Radiation-induced heart disease (RIHD) has been associated with poorer long-term OS in breast and lymphoma survivors (16, 17). For locally advanced NSCLC patients, the impact of cardiac irradiation on OS has not been well characterized because RIHD latency was thought to be longer than the typical OS. However, NSCLC patients are generally older than breast cancer or lymphoma patients, have more underlying cardiopulmonary conditions and common risk factors for ischemic heart disease, and receive higher target radiation doses. Interest in RIHD after NSCLC radiation therapy has therefore increased with the emergence of evidence suggesting that RIHD affects OS earlier than was previously thought (18, 19).

In this post-hoc analysis of the prospective data from IDEAL-CRT (20), we aimed to identify the impact of cardiac irradiation on the all-cause death rate (DR) using a dose-volume histogram-wide analysis approach based on principal components analysis (PCA). We further attempted to localize to specific cardiac substructures the associations seen between whole-heart dosimetry and DR, because whole heart avoidance may not be feasible in clinical practice. To explore pathophysiologic connections between cardiac irradiation and survival, we evaluated electrocardiogram (ECG) changes after irradiation.

**Methods and Materials**

**Population**

Data were analyzed for 78 of all 82 patients with stage IIB/III NSCLC who were recruited and treated in IDEAL-CRT, a phase 1/2 trial of isotoxically escalated CRT, which delivered 63 to 73 Gy in 30 fractions over 6 weeks, concurrently with 2 cycles of vinorelbine and cisplatin. Four patients were excluded, 1 because of corrupted radiation therapy planning archival records, 2 because of replanning during treatment, and 1 because of treatment termination after toxicity after 5 fractions resulting in very low heart doses.

**ECG scoring**

The ECGs obtained at baseline and 6 months after CRT were assessed by 2 cardiologists (S.R. and A.K.) in a blinded manner for the following characteristics: normal ECG, new rhythm changes compared with baseline (sinus tachycardia/bradycardia, conduction abnormalities such as bundle branch block, atrial fibrillation), and ischemic or pericarditis-like changes (new or worsening ST and T wave changes compared with baseline). ECG changes between
the 2 time points were then scored dichotomously as present or absent (“any ECG change”).

Processing of radiation therapy dosimetric data

Treatment plans were imported into the open-source Computational Environment for Radiotherapy Research (CERR) software written in MATLAB R2012b (Mathworks, Inc, Natick, MA). Whole-heart contours delineated by physicians at participating centers were checked by DL and SV. The pericardium, right atrium (RA), right ventricle (RV), left atrium (LA), left ventricle (LV), and AV node (AVN) were delineated as individual substructures by SV using a modified version of a validated cardiac atlas (21). The pericardium was defined as a rim volume lying 5 mm or less beyond the heart, and the outlined AVN was expanded by 3 mm superiorly-inferiorly to account for delineation variability. RA-Wall, RV-Wall, LA-Wall, and LV-Wall were defined as wall regions lying 5 mm or less within the RA, RV, LA, and LV contours, respectively.

Differential-dose-volume histograms (dDVH) with 1-Gy dose-bins were constructed for the whole heart and all substructures and were exported to SPSS.23 (IBM Corp., Armonk, NY) and R 3.2.3 (R Foundation, Vienna, Austria) for further processing. Separate principal components analyses (PCA) were carried out for the whole heart and for each cardiac substructure, representing patients’ dDVHs as linear sums of structure-specific orthogonal principal components (PCs) and the population-averaged dDVH (Appendix A; available online at www.redjournal.org) (22-26). The scores of the PCs in these linear sums reflect the degrees to which they are present in each patient’s dDVH. For each cardiac structure, PCA allowed the highly correlated dose distributions of the whole patient group to be efficiently approximated by a truncated set of PCs, specifically the 10 highest-ranked PCs obtained from PCA for that specific structure. Scores of the initially obtained PCs were uncorrelated across the patient group, each PC describing a unique and independent portion of the dosimetric variability. However, these PCs contained numerous peaks, obscuring their physical interpretation. We therefore used varimax rotation to simplify the PC structure (27), applying an orthogonal rotation to the truncated set of PCs. The rotated PCs are more easily interpretable, mostly having nonnegligible amplitudes across only narrow dose regions, although their scores are no longer orthogonal.

Statistical analysis

Univariable and multivariable analyses (UVA/MVA) of hazard ratios (HRs) for the all-cause death rate (DR) (measured from the start of treatment) were performed with Cox proportional hazards regression. Factors analyzed for association with DR were as follows: clinical (patient and treatment) characteristics, ECG changes, and scores of the 10 highest-ranked whole-heart dosimetry PCs. Relevant clinical factors, ECG changes, and PCs having \( P \) values \( \leq 0.20 \) on UVA were initially included in multivariable models, and stepwise bidirectional variable elimination (28) was performed to find the model with the lowest Akaike information criterion (AIC) score (29).

The false-discovery rate for significant associations after multiple hypothesis testing was controlled using the Benjamini-Hochberg step-up procedure to identify positive discoveries (Appendix B; available online at www.redjournal.org). The predictive abilities of multivariable models were characterized using Harrell’s concordance (C) statistic (30, 31). The C statistic of a model is 1.0 if for all possible pairs of patients, it correctly predicts which patient has the longer survival. A value of 0.5 indicates a model performance no better than chance.

Associations between dichotomized ECG changes and the scores of PCs significantly associated with DR on MVA were tested using logistic regression.

Two approaches were used to further localize the associations seen between DR and whole-heart dosimetry to specific cardiac substructures. The first involved UVA/MVA of associations between DR and the scores of individual cardiac substructure PCs (ss-PCs). To avoid excessive multiple testing, we studied only ss-PCs closely aligned with “heart-PCmax,” the whole-heart PC most strongly associated with DR, using a normalized dot product (NDP) criterion described in Appendix C (available online at www.redjournal.org) to assess closeness of alignment.

The second approach was a graphic interrogation of the shapes of the heart dose distributions of all 78 patients, mapped to a single reference geometry using an in-house MATLAB program (described in detail in Appendix D; available online at www.redjournal.org). Binary masks were created from each patient’s whole heart and left and right atria and ventricles, and registered to the corresponding masks of a reference patient by affine transformation. 3D dose distributions were mapped to the reference geometry through the same affine transformations, and a threshold was applied to identify the region where dose was associated with the peak in heart-PCmax (as quantified in the Results section) for each patient. These high-dose regions were visualized by taking 2D projections through the reference geometry in each principal anatomic plane (transverse, coronal, sagittal), producing images with pixel values representing the percentage of patients for whom the projected high-dose region was present at each point in the plane. Projections were convolved with a Gaussian smoothing kernel (3-mm standard deviation) to avoid identification of features smaller than the typical registration error. This process was carried out for both for the whole heart and for each cardiac substructure, allowing visual localization of the high-dose peak.
Results

Population, ECG, and radiation therapy dosimetry data

Patient and treatment data are detailed in Table 1. ECG changes are also summarized in the table, together with whole-heart and cardiac substructure dosimetry. Fifty-three patients had analyzable ECGs both at baseline and 6 months after radiation therapy, and 20 patients (38%) had documented changes. The mean whole-heart dDVH is plotted in Figure 1, alongside the 10 varimax-rotated whole-heart PCs that described more than 95% of total variance.

Associations between OS, clinical characteristics, ECG changes, and whole-heart dosimetry

Results from UVA are shown in Table 2. Patients with larger planning target volumes (PTVs) or “any ECG change” had significantly higher HRs for DR (P = .04 and .03, respectively). However, when analyzed separately, ischemic/pericarditis-like ECG changes and conduction ECG changes were not statistically significantly associated with DR. The presence of an abnormal baseline ECG was not significantly associated with DR (Table 2) or with onset of any ECG change at 6 months after treatment.

Higher DR was significantly associated with larger Heart-PC6 scores (P = .009) (Table 2). Heart-PC6 has a prominent peak at 63 to 69 Gy and a dip at 0 to 4 Gy (Fig. 1); therefore, in patients with high Heart-PC6 scores, heart volumes receiving 63 to 69 Gy (VHeart-63-69) and 0 to 4 Gy (VHeart-0-4) are, respectively, relatively large and small. Higher DR is more plausibly linked to larger volumes receiving high doses than to smaller volumes receiving low doses—an interpretation supported by a significant association between VHeart-63-69 and DR (HR = 1.13, P = .03) but not between VHeart-0-4 and DR (HR = 1.002, P = .76). Heart-PC6 was not significantly correlated with PTV size (Pearson correlation r = .21; P = .06) or with prescribed dose (r = .08; P = .51) (Appendix E; available online at www.redjournal.org).

Significant correlations between DR and PTV size, “any ECG change,” and Heart-PC6 remained classified as positive discoveries when the false-discovery rate (FDR) was limited to 20% by the Benjamini-Hochberg procedure. The multivariable model judged best according to the AIC retained Heart-PC6 (P = .02), “any ECG change” (P = .04), and PTV size (P = .08) as factors associated with DR (Table 3) and had a good Harrell’s C statistic of 0.76 (32).

Associations between cardiac substructure dosimetry and OS

The hearts of 62 patients received doses in excess of 63 Gy (the lower end of the peak of Heart PC6), and in 82% of these patients ≥1 cm³ of heart received ≥63 Gy. High dose levels were concentrated in the left atrium and overlying pericardium (Fig. 2); specifically, doses ≥63 Gy were delivered to the pericardium in all 62 patients, to LA-Wall in 48 (77%), RA-Wall in 22 (36%), LV-Wall in 18 (29%), RV-Wall in 16 (26%), and AVN in 2 (3%) patients. In the 20 patients with top quartile Heart-PC6 scores, the median heart and LA-Wall fractional volumes receiving ≥63 Gy (VHeart63, VLA-Wall63) were 4% (range, 1%-18%) and 16%
LA-Wall-PC6 score superseding Heart-PC6 (Table 3). This model’s Harrell’s C statistic was good at 0.75.

Scale of OS variation with heart dosimetry and ECG changes

Tables 2 and 3 list DR hazard ratios for the factors studied on UVA and MVA. The scale of association between $V_{LA-Wall-63}$ and DR can be seen in survival curves plotted in Figure 3: for patients with $V_{LA-Wall-63}$ values below or above the median level of 2.2%, median OS was 39.2 and 27.9 months, respectively. At 24 months after treatment, survival was 23% higher (81% vs 58%) for patients with less highly irradiated atrial wall volumes. The scale of association between DR and ECG changes is shown in the survival curves split by the presence or absence of any ECG change, also plotted in Figure 3.
Correlations between ECG changes and dosimetry

Correlations between “Any ECG change” and scores for Heart-PC6, Pericardium-PC5, and LA-Wall-PC6 were not significant ($P = .90, .77, \text{ and } .44$, respectively) (Appendix G; available online at www.redjournal.org).

Discussion

To our knowledge, this is the first study to use a DVH-wide analysis based on principal components to explore associations between heart irradiation and death rate in NSCLC patients, rather than using discrete dose-volume point
metrics. It is also the first to analyze ECG changes and detailed cardiac substructure dosimetry in relation to DR in these patients.

We have found higher DR to be significantly associated with the presence of “any ECG change” 6 months after radiation therapy, and with large PTV size and larger values of $V_{\text{Heart-63-69}}$, the whole-heart volume receiving 63 to 69 Gy. Cardiac doses of 63 to 69 Gy were concentrated in the left atrium and overlying pericardium, and correspond to 64 to 73 Gy equivalent dose in 2-Gy fractions (EQD2) for $\alpha/\beta = 3$ Gy. The scale of associations between DR and heart and substructure volumes receiving 63 Gy was substantial, despite median values of these volumes being low (2%, 5%, and 8% for whole-heart, pericardium, and LA-Wall, respectively). Given that $V_{\text{Heart-63-69}}$ was not significantly correlated with PTV size or prescribed dose, the association between heart dose and DR is likely independent of these latter 2 factors; indeed, both PTV size and Heart-PC6 are retained in the whole-heart multivariable model judged best by the AIC criterion, whereas prescribed dose is not significantly correlated with DR on univariable analysis.

We have additionally explored the impact on DR of the presence of N2/3 disease, and of subcarinal nodal involvement (Appendix H; available online at www.redjournal.org). On univariable analysis, neither N2/3 disease nor involvement of subcarinal nodes was significantly associated with DR ($P = .42$ and .12, respectively). After the addition of these factors into the multivariable models of Table 3, heart and left atrial wall PC6 remained significantly associated with DR ($P = .03$, with very slightly reduced HRs), whereas subcarinal nodal involvement was also retained in the multivariable model judged best on AIC ($P = .07$). In this dataset, then, there is no indication that nodal N2/3 disease or subcarinal nodal involvement was a confounder of the observed associations between cardiac dosimetry and DR.

Because of the proximity of the heart to lung tumors and nodes, it is difficult to avoid the entire heart when escalating tumor dose. It would therefore be useful to identify specific radiosensitive cardiac substructures to spare preferentially, but few data exist regarding cardiac substructure dosimetry. Although irradiation of the left atrial wall was significantly associated with DR in our study, it was not possible to determine whether this was because damage to this structure was particularly critical, or whether the association simply reflects the strong correlation between whole-heart and left atrial volumes receiving 63 to 69 Gy (Spearman correlation $r = 0.88$, $P < .01$).

A recent review found no consensus on heart dose constraints used in NSCLC treatments, with most studies setting very lenient constraints especially at higher heart dose levels (33). In IDEAL-CRT, upper limits of 60, 53, and 45 Gy were placed on $D_{33\%}$, $D_{57\%}$, and $D_{100\%}$,
respectively, the lowest doses delivered to the most highly irradiated 33%, 67%, and 100% of the heart (20). One study set a strict maximum heart dose limit of 63 Gy (34), and in light of the associations we have seen between DR and V\textsubscript{Heart}63-69 we are presently investigating whether this limit can be met while delivering the 63- to 73-Gy IDEAL-CRT range of prescribed doses. The lack of well-defined heart constraints reflects the scarcity of studies exploring the dose dependence of RIHD after radiation therapy for NSCLC.

Our results provide direct evidence that DR is associated with cardiac irradiation after radiation therapy for NSCLC. This adds to existing indirect evidence from the post-operative radiation therapy (PORT) meta-analysis, which demonstrated a 7% absolute reduction in 2-year OS and higher rates of non-cancer-related deaths for irradiated compared with nonirradiated NSCLC patients (35). Analysis of the SEER database found that this increased risk of death existed in patients treated with PORT between 1983 and 1988, but not between 1989 and 1993, possibly because of better normal tissue sparing after the introduction of conformal radiation therapy and higher-energy linear accelerators rather than cobalt machines (36). Greater heart toxicity and mortality rates have also been reported for NSCLC patients with irradiated left-sided rather than right-sided tumors (36, 37). Studies have found negative associations between OS and non-radiation therapy-related cardiac morbidity in NSCLC patients, suggesting that the additive effect of RIHD has the potential to further worsen OS (38, 39).

Radiation-induced fibrosis is thought to be a key mechanism in the development of cardiac dysfunction after radiation therapy. In rats, fibrosis accumulation and dose-dependent decreases in end-diastolic diameter were seen 1 month after single fractions of 15 or 20 Gy, and deaths due to cardiac failure occurred after 22.5 Gy (40, 41). The impact of atrial irradiation on survival was demonstrated by the higher survival seen when atria were specifically spared during heart irradiation (40).

Atrial fibrosis is commonly seen in patients with atrial fibrillation (AF) and plays an important role in the pathophysiology of AF (42-45). Continuous AF can lead to LV dysfunction, increased LA pressure, and impaired atrial contractility, and it has been associated with worse clinical outcomes, including stroke (46). A surrogate for fibrosis, late gadolinium enhancement (LGE) on magnetic resonance imaging, has been seen in the left atrial walls of patients with AF. In patients with esophageal cancer, LGE has been seen in areas of heart receiving 40 Gy, and more so in regions receiving 60 Gy; however, it is not seen outside radiation fields (47). This dose effect is supported by evidence from an esophageal cancer study that found microvasculature circulation obstruction in 0%, 43%, and 68% of myocardial segments receiving 0 Gy, 40 Gy, and 60 Gy, respectively (48, 49). In another study, 14% of esophageal cancer patients had symptomatic cardiac disease 5 years after radiation therapy, the risk varying with the fractions of whole-heart volumes receiving ≥45 Gy, 50 Gy, and 55 Gy (50). In summary, imaging studies have demonstrated radiation dose-related cardiac changes in patients, but further work is required to directly associate these changes with morbidity and mortality.

Some limitations of our study must be acknowledged. First, although it was a prospective study, our analysis was post hoc and lacked comorbidity or smoking status data, which may be additive risk factors for RIHD. Second, the resting 12-lead ECG has limited value as an indicator of subtle pathologic changes within the heart (51, 52). However, in a similar population over the age of 65 without lung malignancies but with baseline ECG changes, the rate of nonfatal and fatal cardiovascular events at 6 months was only around 2% (53). Thus, the higher rate of ECG changes (38%) observed at 6 months in this study is likely due to the effect of radiation therapy.

Third, the study was relatively small, and its findings must consequently be interpreted with caution. Although we found DR to be associated with dosimetry and ECG changes, we could not distinguish truly cardiac-related deaths from cancer-related deaths because there was a lack of cardiac-specific morbidity or mortality data, and all patients with early death experienced tumor relapse. Recording of cause of death is complicated because deaths of radiation therapy patients after cardiac arrest could be scored as cancer related.

Fourth, although we found an association between high doses to left atrium and poorer survival, the mechanism remains unclear. Although we used a validated atlas (21) to define the cardiac substructure, there remains some uncertainty in our substructure outlines resulting from motion. Finally, although PCA provides a very efficient way of reducing many highly correlated dosimetric variables to a few factors, the clinical interpretation of the resulting varimax-rotated PCs can be challenging.

Conclusion

In this small cohort of NSCLC patients we have seen significant associations between all-cause death rate and higher heart volumes receiving 63 to 69 Gy (particularly the left atrial wall). The observed associations suggest that small volumes of heart receiving high radiation doses may have a negative impact on survival, greater and more acute than that seen in breast cancer and lymphoma patients who are treated with lower radiation doses. Our study is hypothesis generating and requires further work to establish a causal relationship between radiation therapy and mortality. The pathophysiology of acute RIHD needs to be determined in prospective functional imaging studies before we recommend modification of treatment plans on the basis of these initial results, for example, to reduce heart doses receiving ≥63 Gy, particularly if this compromises dosimetric PTV coverage. Our finding of an association
between DR and ECG changes at 6 months after treatment does, however, tentatively suggest a link between DR and RT-induced cardiac damage.

Given the armory of intensity modulated photon and ion beam radiation therapy technology available, outcomes of dose-escalated NSCLC treatments may be improvable in future by means of cardiac-sparing dose escalation techniques, given greater knowledge of links between survival, cardiac pathophysiology, and whole-heart and substructure dosimetry.

References

34. RTOG 1106/ACRIN 6697: Randomized phase II trial of individualized adaptive radiotherapy using during treatment FDG-PET/CT and modern technology in locally advanced non-small cell lung cancer (NSCLC). Available at: https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1106.